State Street Corp Has $29.72 Million Stock Holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

State Street Corp grew its holdings in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) by 10.4% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 2,049,542 shares of the company’s stock after acquiring an additional 193,321 shares during the period. State Street Corp owned about 2.11% of ARS Pharmaceuticals worth $29,718,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. First Turn Management LLC acquired a new position in ARS Pharmaceuticals during the 3rd quarter worth about $8,603,000. Jacobs Levy Equity Management Inc. raised its holdings in ARS Pharmaceuticals by 78.9% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 653,048 shares of the company’s stock worth $9,469,000 after purchasing an additional 288,021 shares during the last quarter. Miura Global Management LLC bought a new stake in shares of ARS Pharmaceuticals in the 3rd quarter valued at $3,915,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of ARS Pharmaceuticals by 766.1% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 234,537 shares of the company’s stock worth $3,401,000 after buying an additional 207,456 shares during the period. Finally, Raymond James & Associates bought a new position in ARS Pharmaceuticals during the third quarter worth $2,969,000. Institutional investors and hedge funds own 68.16% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on SPRY shares. Leerink Partners increased their price target on ARS Pharmaceuticals from $21.00 to $25.00 and gave the stock an “outperform” rating in a report on Friday, September 20th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $30.00 price objective on shares of ARS Pharmaceuticals in a research note on Tuesday, October 8th. Finally, William Blair upgraded shares of ARS Pharmaceuticals to a “strong-buy” rating in a research report on Friday, August 30th. Four research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, ARS Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $24.00.

Insider Activity

In other ARS Pharmaceuticals news, CEO Richard E. Lowenthal sold 100,000 shares of ARS Pharmaceuticals stock in a transaction dated Tuesday, October 8th. The shares were sold at an average price of $13.83, for a total value of $1,383,000.00. Following the sale, the chief executive officer now owns 1,346,494 shares of the company’s stock, valued at approximately $18,622,012.02. The trade was a 6.91 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Laura Shawver sold 14,772 shares of the company’s stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $13.75, for a total value of $203,115.00. Following the completion of the transaction, the director now owns 210,346 shares in the company, valued at approximately $2,892,257.50. The trade was a 6.56 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 1,258,058 shares of company stock worth $19,369,686 over the last three months. 40.10% of the stock is currently owned by insiders.

ARS Pharmaceuticals Stock Down 1.2 %

Shares of SPRY opened at $11.18 on Friday. The business’s fifty day moving average is $14.37 and its 200 day moving average is $12.43. ARS Pharmaceuticals, Inc. has a 12-month low of $5.02 and a 12-month high of $18.51. The stock has a market cap of $1.09 billion, a P/E ratio of -21.92 and a beta of 0.88.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.